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The objective of this study was to evaluate the acute and subacute toxicity (28 days) of the ethanol extract of Z. zerumbet rhizomes
(EEZZ) via the oral route in Wistar rats of both sexes. In the acute toxicity study, Wistar rats were administered a single dose of
15gkg−1 of body weight by gavage, and were monitored for 14 days. EEZZ did not produce any toxic signs or deaths; the 50%
lethal dose must be higher than 15gkg−1. In the subchronic toxicity study, EEZZ was administered by gavage at doses of 1000,
2000 and 3000mg/kg daily for 4 weeks to Wistar rats. The subacute treatment with EEZZ did not alter either the body weight gain
or the food and water consumption. The hematological and biochemical analysis did not show signiﬁcant diﬀerences in any of the
parameters examined in female or male groups. Necropsy and histopathological examination, did not reveal any remarkable and
treatment related changes. A no-observed adverse-eﬀect level for EEZZ is 3000mgkg−1 for rats under the conditions of this study.
Hence, consumption of EEZZ for various medicinal purposes is safe.
1.Introduction
Zingiberaceae is widely distributed throughout the tropics
particularly in Southeast Asia [1]. Zingiber zerumbet (L)
Smith, commonly known as the pinecone or shampoo
ginger, is a perennial, tuberous root herb plant that has
gained much interest from scientists all over the world
because of its high medicinal values. This herbal plant has
been cultivated for thousands of years as a spice and also
for medicinal purposes, that is, as a cure for headaches,
swelling, colds, ulcers, sores and loss of appetite, nausea,
and even menstrual discomfort and has been introduced
to many parts of the world as a rich source of compounds
of phytomedicinal interest [2]. The rhizome of Z. zerumbet
has been used to treat various ailments in Asian and Arabic
traditional medicine since ancient times [3, 4]. It is used in
local traditional medicine as a cure for swelling, sores, and
loss of appetite. The juice of boiled Z. zerumbet rhizomes has
been used for the treatment of worm infestation in children.
Z. zerumbet has been shown to inhibit prostaglandin-
induced paw oedema, a commonly used acute inﬂammatory
reaction and the eﬃcacy is equivalent to the nonsteroidal
anti-inﬂammatory drug, mefenamic acid [5]. The ethanol
extracts of Z. zerumbet signiﬁcant antipyretic activity in
Brewer’s yeast induced pyrexia in rats [6]. Z. zerumbet is
also used in herbal medicinal practice for the treatment of
rheumatological conditions and muscular discomfort [7].
Furthermore, the methanol extract of Z. zerumbet possesses
inhibitory eﬀectson platelet-activating factorand against the
D e n 2v i r u sN S 2 B / N S 3p r o t e a s ea c t i v i t y[ 8, 9].
Despite knowledge of biological activities of Z. zerumbet
rhizomes, toxicological studies are very few; it has been
documented that the aqueous extract of Z. zerumbet at
2000mg/kg body weight did not cause any behavioral
changestothebroilerchickensimmediatelyafteritsadminis-
tration indicated by normal movement and drinking behav-
ior [10]. Although herbal medicines/dietary supplements are
not covered under US-FDA drug-regulatory criteria due to2 Evidence-Based Complementary and Alternative Medicine
the consideration of their being safe, their safety proﬁle
may not have been adequately documented. Hence, pre-
clinical acute and subchronic toxicological evaluations using
Organisation for Economic Cooperation and Development
(OECD) guidelines need to be undertaken to establish safety
proﬁles of drugs of herbal origin [11]. In the previous study,
weobservedthattheethanolextractsfromZingiberzerumbet
(EEZZ) with the capacity to reduce the accumulation of
visceral fat and improved hyperlipidemia in high-fat-diet-
induced obese rats by increasing lipid metabolism [12].
The usability of EEZZ in human cholesterol/lipid/obesity
indicationscouldbeconsiderable,butthetoxicologicalstudy
on EEZZ is limitation. The present study therefore aims at
investigating the acute and subchronic oral toxicity of EEZZ
applying the recommended OECD guidelines for safety or
dose-dependent toxicity in rats.
2.Materials
2.1. Plant Material and Extraction. Z. zerumbet rhizomes
were purchased from a local market in Dongshan District
(Tainan City, Taiwan) during October 2010. Macroscopic
and microscopic examinations, as well as thin-layer chro-
matography and high-performance liquid chromatography,
were used to conﬁrm the authenticity of the plant material
provided (this analysis was performed by Dr. Hong T. Y.,
Department of Biotechnology, Collage of Pharmacy and
Health Care, Tajen University). Random ampliﬁed polymor-
phic DNA analysis of the Z. zerumbet rhizomes supplied
was also performed to identify DNA polymorphisms. The
voucher specimen (Lot No.20101018) has been deposited
in our laboratory. Extraction was performed by maceration
and air dried, and 5kg of pulverized Z. zerumbet rhizomes
was added to 10 L of 95% ethanol at room temperature
for 7 days and was occasionally shaken. The ethanol extract
of Z. zerumbet rhizomes (EEZZ) was evaporated to dryness
under reduced pressure for the total elimination of alcohol,
followed by lyophilization, yielding approximately 575g of
dry residue (w w−1 yield: 11.5%). EEZZ was kept at −20◦C
until use and suspended in distilled water.
2.2. Phytochemical Screening. To determine the chemical
constituents, qualitative phytochemical screening of EEZZ
was carried out following standard procedures routinely
[13] and revealed alkaloids (Meyer and Dragendoﬀ’s test),
tannins (FeCl3 test), saponins (frothing test), lipids (Watt-
man paper test), ﬂavonoids (Schinoda’s test), glycosides
and polyoses (NaCl, and Fehling’s solutions A and B),
anthraquinones (ether-chloroform and NaOH), phenols
(FeCl3), polyphenols (K3Fe(CN)6), and terpenoids (Liber-
man Burchard’s test).
2.3. Animals. Adult female and male Wistar rats (aged 2
months, weighing 181–199 and 185–205g, resp.) were
obtained from the National Laboratory Animal Cen-
ter (Taipei City, Taiwan). They were maintained in a
temperature-controlled room (25 ± 1◦C) on a 12h:12h
light-dark cycle (lights on at 06:00h) in the animal center
(Tajen University, Pingtung County, Taiwan) and had free
access to standard commercial diet and tap water. All animal
procedures were performed according to the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health, as well as the guidelines of the Animal
Welfare Act. These studies were conducted with the approval
of the Institutional Animal Care and Use Committee
(IACUC) at Tajen University (approval number: IACUC 99-
16; approval date: September 9, 2010).
2.4. Acute Oral Toxicity Study. The acute oral toxicity study
was conducted using the limit test procedure according to
OECD test guidelines on acute oral toxicity test 401 [14].
Twenty (10 males and 10 females) 8-week-old Wistar rats
were housed individually in hygienic metabolic cages. EEZZ
was administered to rats at a daily dose of 15gkg−1 of body
weight. EEZZ was solved in distilled water and 10mLkg−1
of the sample was fed by gavage thrice daily, the interval
time of the extract administration was 8h to mimic the
medication dose frequency of human. The rats were not
fed for 3h following administration. The signs of toxic
eﬀects and/or mortality were observed carefully every 0.5
to 1h after administration on the ﬁrst day, followed by
daily observation, and the body weights were recorded for
consecutive 14 days. LD50 value was calculated following the
previous method [15].
2.5. Subchronic Oral Toxicity Study. The method was per-
formed according to the OECD test guidelines with slight
modiﬁcations [16]. Eight-week-old Wistar rats were housed
in the same conditions as described above. The eighty
animals were randomly divided into four groups containing
20 rats each (10 females and 10 males). EEZZ dissolved in
distilled water was administered to groups of rats at the
concentrations of 1000, 2000, and 3000mgkg−1 by gavage
of 10mLkg−1 for 4 weeks. The control group received
the vehicle only. The animals were observed for signs of
toxicity and mortality throughout the experimental period.
The weight of each rat was recorded at weekly intervals
throughout the course of the study. Food and water con-
sumption were measured three times a week. At the end of
the 4-week experiment, the animals, fasted for 12h, were
sacriﬁced by decapitation under anaesthesia with sodium
pentobarbital (30mgkg−1) administered intraperitoneally.
Blood was collected into two tubes: tube 1 containing EDTA
was processed immediately for haematological parameters;
tube 2 without additive was centrifuged at 3000× ga t4 ◦C
for 10min to obtain serum (stored at −20◦C until analysis).
The organs (kidneys, liver, lungs, heart, testes and glands
annexes,ovaries,spleen,andpancreas)wereweighted.Organ
samples were ﬁxed in 10% formalin for histopathological
examination.
2.6. Hematological and Biochemical Analysis. Hematological
analysis was performed using an automatic hematological
analyzer (Coulter STKS, Beckman). Parameters included red
blood cell (RBC) count, white blood cell (WBC) count,
hemoglobin (Hb), hematocrit (Hct), mean corpuscularEvidence-Based Complementary and Alternative Medicine 3
volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC), red
cell distribution width (RDW), platelets count, and mean
platelet volume (MPV). For biochemical analysis, following
parameters were determined: glucose; blood urea nitrogen
(BUN); creatinine; aspartate aminotransferase (AST); ala-
nine aminotransferase (ALT); total cholesterol; triglycerides;
high-density lipoproteins (HDL); amylase; gamma-glutamyl
transpeptidase (GGT); total, direct and indirect bilirubin.
These levels were determined using an autoanalyser (Hitachi
7080, Japan).
2.7. Pathological Examination. All animals were subjected to
necropsy at the end of the toxicity studies, or earlier in case
of death. Necropsy was performed to analyze the macro-
scopic external features of the heart, liver, spleen, lungs,
kidney, adrenal gland, esophagus, stomach, small intestine
(fragment of 6-7cm), hypophysis, hypothalamus, brain, and
reproductive organs (uterus and ovary or testicle, prostate,
epididymis, seminal vesicle, and vas deferens). These organs
were carefully removed and weighed individually. Organ
weights were expressed in absolute and relative terms (g
and g 100g−1 of body weight, resp.). Histopathological
investigation was done according to methods described in
literature [17]. In addition to the organs mentioned above,
the pancreas, lymph node, and bladder were also detected.
Brieﬂy, tissue samples were prepared routinely and cut
into 2µm slides and stained with haematoxylin-eosin, then
examined using a light microscope.
2.8. Statistical Analysis. Data are expressed as the mean
± standard deviation (SD) for each group of animals at
the number (n) indicated in tables. Statistical analysis was
performed with one-way analysis of variance (ANOVA). The
Dunnett range posthoc comparisons were used to determine
the source of signiﬁcant diﬀerences where appropriate. A P
value <.05 was considered statistically signiﬁcant.
3. Results
3.1. Phytochemical Screening of EEZZ. The phytochemical
screening of EEZZ revealed the presence of the following
classes of chemical compounds: alkaloids, saponins, ﬂa-
vonoids, tannins, terpenoids, phenols, polyphenols, and sug-
ars.
3.2. Acute Toxicity. The mean body weight of female rats
increased from 190.2 ± 8.2g to 221.1 ± 9.7g during the
14 days, and that of males increased from 194.7 ± 8.9g
to 239.7 ± 12.8g (data not shown). No mortalities had
occurred during the study and clinical observations and
measurements did not indicate evidences of substance-
related toxicity. After sacriﬁce on the 14th day, macroscopic
and gross pathology observations conducted at the necropsy
examination revealed no visible lesions in any animals. Thus,
no evidence of acute toxicity of EEZZ in rats was found. The
oral LD50 values for female and male rats must be greater
than 15gkg−1.
3.3. Subacute Toxicity. No toxicity signs (such as piloerec-
tion, alteration in the locomotor activity, or diarrhea) or
deaths were recorded during the 4 weeks of treatment via
oralroutewithEEZZatdosesof1000,2000,or3000mgkg−1.
No signiﬁcant diﬀerences were found between the initial and
ﬁnal body weight of the rats treated with EEZZ and control
rats (Table 1). A similar absence of toxic eﬀect was observed
in the case of food and water consumption (Table 1).
3.4.HematologicalandBiochemicalParameters. Thehemato-
logicalp r o ﬁleo fthetr eat edandc o ntr olgr oupsar ep r ese nt ed
in Table 2. EEZZ did not induce any signiﬁcant change in
the hematological parameters such as WBC counts, total
leukocyte count, hemoglobin, hematocrit, total erythrocyte
count, erythrocyte indices (MCV, MCH, and MCHC),
platelets count and MPV (Table 2).
Thebiochemicalproﬁleofthetreatedandcontrolgroups
are presented in Table 3. The plasma levels of glucose, BUN,
creatinine, AST, ALT, total cholesterol, triglyceride, and HDL
of rats treated with EEZZ up to 3000mgkg−1 were found to
be comparable with those of the control group at end of the
28 days treatment. There was no signiﬁcant diﬀerence in the
plasma levels of amylase, GGT and total, direct and indirect
bilirubin between vehicle-treated, and EEZZ-treated rats at
any dosage (Table 3).
3.5. Morphological Parameters. T h ea b s o l u t ea n dr e l a t i v e
tissue weights were not altered by EEZZ treatment (Tables
4 and 5). No treatment-related macroscopic ﬁndings were
observed in treated animals at necropsy. For the histolog-
ical investigation, no pathological changes were observed
in the hearts of animals in any group (Figure 1). Some
inﬂammation and cell degeneration were seen in kidneys
and livers of the animals treated with EEZZ; however, the
changes were also detected in the control group and had no
connectionwiththedoses(Figure 1).Otherorgansincluding
spleen, adrenal gland, thymus, thyroid gland, brain, uterus,
testis, prostate, pancreas, absorbent gland, and bladder
showed no sign of pathological changes compared with the
corresponding organs of the controls.
4. Discussion
The results of the acute toxicity study indicated that EEZZ
via oral route with the doses up to 15gkg−1 did not produce
any sign of toxicity or death in rats, suggesting a LD50 above
15gkg−1 via oral route. Thus, referring to the Hodge and
Stemer scale [18], the orally administered EEZZ could be
considered practically nontoxic.
Repeated dose toxicity studies are conducted to evaluate
the adverse eﬀects of a test substance after prolonged use and
are carried out to provide information about the possible
health hazards likely to arise from repeated exposure over
a relatively limited period of time including information
about target organs, the possibilities of cumulative eﬀects,
and an estimate of the dose at which there is no observed
adverse eﬀect. The subacute treatment indicated that EEZZ
in doses of 1000, 2000, and 3000mgkg−1 per day during 284 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Photomicrographs of heart of control (a) and 1000, 2000, and 3000mg kg−1 EEZZ-treated rat (b, c, d), kidney of control (e), and
1000, 2000, and 3000mg/kg EEZZ-treated rat (f, g, h), and liver of control (i) and 1000, 2000, and 3000mg/kg EEZZ-treated rat (j, k, l)
stained with hematoxyline and eosin (100x).
consecutive days did not produce any deaths or clinical signs
oftoxicity.Thedosesemployedinthepresentstudyrepresent
up to 30 times more than those used as an analgesic and
anti-inﬂammatory agent [6, 19]. A decrease in body weight
would be an indicator of adverse eﬀects [20, 21]; there were
no signiﬁcant changes in animal behaviour, food and water
consumptions, and in body weight gain in EEZZ-treated
group at any dosage. Analysis of blood parameters is relevant
to risk evaluation of alterations of the haematological
system in humans [22]. No signiﬁcant alterations of the
haematological and biochemical parameters of both male-
and female-treated rats can be attributed to the plant extract.
Kidney is a sensitive organ, whose function is known to
be aﬀected by a number of factors such as drugs including
phytochemicals of plant origin that ultimately lead to renal
failure [23]. Assessment of possible renal damage due to
EERR was made by assaying plasma urea and creatinine
levels [24]. Results show no signiﬁcant alteration in the
plasma urea and creatinine levels due to EEZZ treatment.
Moreover, there was no eﬀect on the levels of AST and
ALT, which are considered to be sensitive indicators of
hepatocellular damage and within limits can provide a
quantitative evaluation of the degree of damage to the liver
[25]. It is reasonable to deduce, therefore, that EEZZ did
not induce any damage to the liver or kidneys. This is
further conﬁrmed by the histological assessment of these
organs, and the fact that plasma cholesterol levels remained
unaﬀected, the latter being an indirect indicator of liver
function [26]. No diﬀerence was observed in the weight and
structure of the other organs between the control and the
treated groups. Altogether, the subchronic study indicates
that EEZZ ingestion did not induce detrimental changes and
morphological alterations in these organs.
Since the oral dose of 3000mgkg−1 per day of EEZZ
administered for 28 consecutive days did not induce any
biochemical, hematological, anatomical, and histopatholog-
ical signs of toxicity, it can be deﬁned as the no-observed-
adverse-eﬀect level (NOAEL) for Wistar rats of both sexes
under the experimental conditions used. Information will
help for future clinical studies of the medicinal safety
and in vivo experimental studies of the pharmacological
potentialities of this mode of administration of the plant
medicine. However, it should be emphasized that this
NOAEL was derived from a subacute study only. Since
toxicity in humans cannot always be entirely extrapolated
fromanimalstudies,clinicalevaluationshouldbeperformed
to precisely deﬁne the safe dosage to advice in humans. For a
more reliable safety evaluation performed on the basis of the10 Evidence-Based Complementary and Alternative Medicine
acceptable daily intake concept, data on the chronic toxicity,
reproductive toxicity, genotoxicity, and carcinogenicity of
EEZZ would also be required.
5. Conclusion
In acute and subchronic toxicity studies we did not ob-
serve mortality or signs of toxicity attributable to the
administration of EEZZ and no signiﬁcant weight loss was
registered. Therefore, the NOAEL for the acute toxicity study
was 15gkg−1 and for the subchronic toxicity study was
3000mgkg−1. According to the dosage levels evaluated in the
subchronic and acute toxicity studies, the LOAEL (Lowest
Observed Adverse Eﬀect Level) was not found for the Z.
zerumbet rhizomes ethanol extract. Thus, the plant, at least
itsethanolextract,couldbeconsideredwithawidemarginof
safety for oral use. Since toxicity in humans cannot always be
entirely extrapolated from animal studies, clinical evaluation
should be performed to precisely deﬁne the safe dosage to
advice in humans.
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